Characteristics of Switchers to Newer Therapies in the NARCOMS Registry (P3.282)
Why this work is in the frame
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Bibliographic record
Abstract
Background: The North American Research Committee on Multiple Sclerosis Registry (NARCOMS) captures self-reported disease modifying therapy (DMT) information and patient-reported outcomes from persons with MS. Previous reports show that those who remain on the same DMT report less disease worsening than those who switch. Objective: Assess characteristics of persons with MS who switch from an parenteral DMT [interferon beta (-1a IM, -1a SC, -1b), glatiramer acetate, natalizumab] to an oral DMT [dimethyl fumarate (DMF), fingolimod (FIN), teriflunomide (TF)]. Methods: US residents who reported a switch from a parenteral DMT to an oral DMT in Spring or Fall survey in 2011-2013 were included in the analysis. Switching to DMF/TF was not captured until Fall 2012. We compared socio-demographic factors, Patient Determined Disease Steps (PDDS) as a measure of disability, and relapse activity as reported at the time of the switch and 6 months later. Results are reported as mean (SD), median (IQR) or [percnt], as applicable. Results: 595 registry participants indicated switching to FIN (n=278), DMF (n=238) or TF (n=79) from a parenteral DMT from 2011-2013. Switchers were 81.7[percnt] female, 51.6(9.8) years old, with mean disease duration of 14.6(8.4) years and 97.9[percnt] had health insurance. Median PDDS of switchers was 3(1, 5), with only 16.8[percnt] reporting PDDS worsening of at least 1 point as compared to 6 months before the switch. Relapse during the 6 months before the switch was reported by 26.1[percnt] and symptom worsening by 35.0[percnt] of the switchers, while 4.7[percnt] (23/486) reported a relapse in the prior 6 months. Conclusion: Follow-up on those taking the oral DMTs provides important information on switching behavior. Most participants that switched reported worsening in PDDS, symptom worsening, and/or switched following relapses. Patient-reported outcomes provide a practical way of describing disease activity and comparing switchers with those remaining on an established DMT.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it